Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia
30 Years
90 Years
Both
Waldenstrom's Macroglobulinemia
Trial Information
Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia
- A medical data collection survey sheet will be filled out by the patient or doctor with
medical information pertaining to how the patient responded to rituximab and other
monoclonal antibodies for use in this study.
- Blood work will be performed to analyze the blood by molecular technology to find the
kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with
the outcome of treatment with rituximab or other monoclonal antibodies.
Inclusion Criteria:
- Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's
macroglobulinemia
Type of Study:
Interventional
Study Design:
N/A
Principal Investigator
Steven Treon, MD, MA, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
02-075
NCT ID:
NCT00142155
Start Date:
January 2002
Completion Date:
March 2007
Related Keywords:
- Waldenstrom's Macroglobulinemia
- monoclonal antibody
- Fc gamma RIII receptor expression
- rituximab
- Waldenstrom Macroglobulinemia
Name | Location |
|---|---|
| Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
